ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2005
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2005. ResMed Inc. designs, manufactures, and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders. The company operates manufacturing facilities in Australia, Germany, France, and the United States, with major distribution sites globally. All share and per-share data have been retroactively adjusted to reflect a two-for-one stock split distributed on September 30, 2005.
Key Financial Metrics
| Metric | Q3 2005 | Q3 2004 |
|---|---|---|
| Net Revenues | $127.1 million | $87.7 million |
| Gross Profit | $80.1 million | $56.4 million |
| Gross Margin | 63% | 64% |
| Operating Income | $24.5 million | $21.0 million |
| Net Income | $16.4 million | $13.9 million |
| Diluted EPS | $0.23 | $0.20 |
| Cash from Operations | $15.9 million | $16.6 million |
| Cash & Equivalents (End of Period) | $129.7 million | $141.6 million |
| Total Debt (Current + Long-term) | $184.5 million | Filing does not provide clear Q3 2004 total |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 45% year-over-year, driven by a 30% organic growth rate and $13.0 million in incremental revenue from recent acquisitions (Saime, Hoefner, Resprecare, and Pulmomed).
- Margin Compression: Gross margin decreased from 64% to 63%. Management attributes this to a higher mix of lower-margin domestic sales and increased manufacturing costs in Australia due to a stronger Australian dollar.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 67% to $44.7 million, largely due to the adoption of SFAS 123(R) stock-based compensation ($2.9 million), increased personnel, and acquisition integration costs. R&D expenses increased 24% to $8.4 million.
- Balance Sheet: Inventories increased 65% to $100.9 million to support production volumes and new product launches (S8 flow generator). Accounts receivable increased 50% to $103.0 million.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A to remain in the range of 33% to 37% of net revenue and R&D between 5% and 8%, including stock-based compensation.
- Capital Expenditures: Significant capital spending ($39.6 million) occurred this quarter, including a $21.0 million land purchase in San Diego for a new corporate headquarters. Construction of new R&D facilities in Sydney is ongoing, with estimated additional costs of $43.8 million.
- Debt Maturity: The company has $113.3 million in convertible subordinated notes maturing on June 20, 2006. Management is reviewing funding needs to refinance or repay these notes if they do not convert.
- Acquisitions: On November 1, 2005 (subsequent event), ResMed agreed to acquire PolarMed AS for $8.0 million plus potential milestones. Purchase price allocations for Saime and Pulmomed are not yet final.
- Risks: Key risks include foreign currency fluctuations, integration challenges with recent acquisitions, reliance on third-party reimbursement, and potential supply chain disruptions from single-source suppliers.
Investor Verification Checklist
- Convertible Notes: Verify the company's strategy and funding availability for the $113.3 million convertible note maturity in June 2006.
- Inventory Levels: Assess the sustainability of the 65% increase in inventory relative to sales velocity and potential obsolescence risks.
- Acquisition Integration: Monitor the realization of synergies and revenue contributions from Saime, Hoefner, Resprecare, and Pulmomed.
- Stock-Based Compensation: Review the ongoing impact of SFAS 123(R) adoption on future earnings and cash flow classification.
- Foreign Exchange: Evaluate the effectiveness of hedging strategies given the exposure to the Australian dollar and Euro.